OTCM
TCLIF
Market cap9mUSD
Aug 26, Last price
0.32USD
Name
Theraclion SA
Chart & Performance
P/E
—
P/S
4.88
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
23.07%
Revenues
2m
Net income
-4m
CFO
-2m
Profile
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY |
|---|---|
| 2023‑12 | |
| Income | |
Revenues | 1,656 |
Cost of revenue | 2,903 |
Unusual Expense (Income) | |
NOPBT | (1,247) |
NOPBT Margin | |
Operating Taxes | (1,049) |
Tax Rate | |
NOPAT | (198) |
Net income | (3,675) |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | 8,777 |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | 1,951 |
Deferred revenue | |
Other long-term liabilities | 6,511 |
Net debt | (5,865) |
| Cash flow | |
Cash from operating activities | (2,485) |
CAPEX | (112) |
Cash from investing activities | (214) |
Cash from financing activities | 7,994 |
FCF | |
| Balance | |
Cash | 7,815 |
Long term investments | |
Excess cash | 7,732 |
Stockholders' equity | (1,388) |
Invested Capital | 15,497 |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | 45,732 |
Price | |
Market cap | |
EV | |
EBITDA | 1,395 |
EV/EBITDA | |
Interest | 1,961 |
Interest/NOPBT | |